top of page


BioMolecular Imaging can help your company navigate the complexities of biomarker development from preclinical research to FIH imaging to approval. We can guide you as you interface with the FDA, CRO’s, and academic imaging sites.

We help you answer some of the most difficult questions like how to de-risk late phase studies by using imaging to gain certainty that a drug candidate has target bioavailability and the required pharmacokinetics is sound science and solid business practice.



BioMolecular Imaging has provided expert advice to corporations and biotech companies across the spectrum of organ systems, molecular targets, molecular probe constructs, and radioisotopes. These extend from early clinical to late clinical to post-approval strategies in clinical roll-out, company acquisitions, clinical indications, and companion diagnostic



Tune into Dr. J. James Frost's blog, podcast, YouTube and social media profiles to stay up to date with bimolecular imaging industry news.



Dr. Frost is a highly published academic investigator. Several representative publications are included for review that span brain, heart and oncology molecular imaging, from early PET and SPECT tracer development to clinical trials.

We reached out to BioMolecular Imaging and Dr. Frost in the process of taking a new imaging agent from preclinical to clinical imaging. Dr. Frost identified several academic imaging institutions for the work and he did the initial vetting from the standpoint of capabilities and timing.

Business Meeting


Molecular and anatomic imaging continues to be an ever increasing and essential component of clinical drug trials. Early stage trials examine target accessibility and drug pharmacokinetics, while later phase studies employ imaging as an early indicator of response or as an efficacy endpoint. New molecular probes from early phase studies become the future diagnostic agents that guide patient stratification for therapy and monitor patient response.

The truly staggering cost of drug development dictates that efficient practices must be employed at every development step. The use of quantifiable and objective imaging endpoints can form the basis of the needed process efficiencies, accelerating development and decreasing costs.

While imaging is an extremely powerful technology, it is a complex process itself. Most companies, however, don’t have the internal imaging expertise required to plan and carry out imaging studies. BioMolecular Imaging can help you to develop your company’s internal strategy; navigate imaging process steps to achieve tactical certainty; interface effectively with the necessary external partners; and maximize power of inference using best practice image analytics.


Thanks for submitting!

bottom of page